Alterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing

Alterity Therapeutics ( (AU:ATH) ) has issued an update.

Alterity Therapeutics reported steady progress in advancing its lead candidate ATH434 toward a pivotal Phase 3 program in Multiple System Atrophy, highlighted by two positive Type C interactions with the U.S. Food and Drug Administration that endorsed key clinical, non-clinical, and manufacturing elements. The company also strengthened its clinical and commercial capabilities with the appointments of Chief Medical Advisor Dr. Daniel Claassen and new board member Ann Cunningham, presented new Phase 2 data suggesting ATH434 slows functional decline in MSA patients, continued discussions with potential pharmaceutical partners, and closed the quarter with a cash balance of A$44.53 million as of 31 March 2026.

New analyses from the ATH434-201 Phase 2 trial, showcased in a late-breaking platform presentation at the American Academy of Neurology meeting, indicated consistent efficacy signals using the novel MuSyCA composite endpoint, reinforcing the drug’s disease-modifying potential. Management said the company remains on track for an End-of-Phase 2 FDA meeting around mid-2026, a key regulatory milestone that could enable initiation of a pivotal Phase 3 trial and potentially enhance Alterity’s strategic positioning and partnering prospects in the neurodegenerative disease space.

The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative disorders, with a lead program targeting Multiple System Atrophy. Listed on the ASX and Nasdaq, the company is advancing its small-molecule candidate ATH434 for patients with this rare and severe movement disorder.

Average Trading Volume: 7,647,295

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$119.6M

See more data about ATH stock on TipRanks’ Stock Analysis page.